Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2031

Conditions
Head and Neck Cancer
Interventions
DRUG

PCC

"PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death."

Trial Locations (4)

54519

NOT_YET_RECRUITING

Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy

57085

NOT_YET_RECRUITING

Centre hospitalier Régional de Metz-Thionville, Ars-Laquenexy

67033

RECRUITING

Institut de cancérologie Strasbourg Europe, Strasbourg

68024

NOT_YET_RECRUITING

Centre Hospitalier de Colmar, Colmar

All Listed Sponsors
lead

Institut de cancérologie Strasbourg Europe

OTHER